Provided By GlobeNewswire
Last update: Sep 8, 2025
MELBOURNE, Australia and SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received binding commitments for a capital raising of A$20.0 million (the “Placement”) of fully paid ordinary shares (“New Shares”) to International and Australian professional investors.
Read more at globenewswire.comNASDAQ:ATHE (11/17/2025, 10:11:37 AM)
3.79
-0.05 (-1.3%)
Find more stocks in the Stock Screener


